Clinical Trials Directory

Trials / Completed

CompletedNCT02684734

Prevalence of Cytomegalovirus Infection in Patients With Quiescent Ulcerative Colitis

Status
Completed
Phase
Study type
Observational
Enrollment
50 (actual)
Sponsor
University of British Columbia · Academic / Other
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

Colitis from reactivation of established cytomegalovirus (CMV) colonization can complicate the clinical course in patients with an acute flare of ulcerative colitis (UC). Accurate and timely detection of active CMV infection or disease with appropriate anti-viral therapy may reduce complications associated with acute UC flare. Limited information is available on the presence of colonic CMV infection in patients with quiescent ulcerative colitis. Prospective studies on factors associated with reactivation of CMV infection during active UC flare and its impact on disease progression are lacking. The hypothesis of this study are as follows: 1) CMV infection is prevalent in patients with ulcerative colitis irrespective of disease severity; 2) The degree of immunosuppression directly impacts CMV infection status in patients with ulcerative colitis

Detailed description

This is cross sectional study at St. Paul's Hospital, a tertiary academic teaching hospital. Subjects ages 19 or greater with quiescent ulcerative colitis present for routine elective surveillance endoscopy will be invited for the study. At enrollment, subjects will be evaluated for clinical and endoscopic disease severity using Mayo score. To be eligible for the study, Mayo score must be \<2. Supplemental blood tests, diagnostic test to determine CMV status, physical examination for extra-intestinal manifestation of CMV and inflammatory bowel disease, and surveillance colonoscopy with colonic biopsy will be done. Patients will be followed longitudinally. Patients will be contacted every three months via their preferred method (telephone or email) until disease flare (clinical partial Mayo Score \> 2) or one year from enrolment. Patients will be asked to contact study coordinator when they are experiencing UC flare.

Conditions

Timeline

Start date
2015-12-01
Primary completion
2019-11-30
Completion
2019-12-01
First posted
2016-02-18
Last updated
2022-05-20

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT02684734. Inclusion in this directory is not an endorsement.